lunedì, 4 maggio 2026

Notizie AIOM – anno XVII

3 Settembre 2019

Atezolizumab Plus Nab-Paclitaxel Approved in Europe for Frontline TNBC

Aug 29, 2019 - The European Commission (EC) has approved the frontline combination of atezolizumab plus nab-paclitaxel for the treatment of adult patients with unresectable locally advanced or metastatic PD-L1–positive triple-negative breast cancer (TNBC), according ...
Leggi tutto

3 Settembre 2019

29 agosto 2019 – Nota Informativa Importante su Mitomycin C 40 mg

3 Settembre 2019

Global public meeting on draft ICH guideline on clinical trials

Aug 30, 2019 - The global guidance for the conduct of clinical trials is currently undergoing a major revision. As part of the worldwide consultation process, the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) is ...
Leggi tutto

29 agosto 2019 – Rilascio online nuovo sistema di rimborso – MEA finanziari

Elotuzumab Triplet Approved in Europe for Multiple Myeloma

Aug 27, 2019 - The European Commission has approved elotuzumab for use in combination with pomalidomide and low-dose dexamethasone (EPd) for the treatment of patients with relapsed/refractory multiple myeloma following 2 or more prior therapies, including lenalidomide and ...
Leggi tutto

Pemetrexed, Bevacizumab, or the Combination As Maintenance Therapy for Advanced Nonsquamous Non–Small-Cell Lung Cancer: ECOG-ACRIN 5508

Pemetrexed or bevacizumab is used for maintenance therapy of advanced nonsquamous non–small-cell lung cancer (NSCLC). The combination of bevacizumab and pemetrexed has also demonstrated efficacy. We conducted a randomized study to determine the optimal maintenance ...
Leggi tutto

26 agosto 2019 – Epatite C: aggiornamento del 26/08/2019 sui pazienti arruolati

Assisted reproductive technology and risk of ovarian cancer and borderline tumors in parous women: a population-based cohort study

The study aimed to investigate if assisted reproductive technology (ART) treatment or a diagnosis of infertility were associated with the risk of ovarian cancer or borderline ovarian tumors (BOT) in parous women. In a population-based register study of 1,340,097 women with ...
Leggi tutto

FDA Wants Male Patients Factored Into Breast Cancer Drug Development

Aug 21, 2019 - The FDA is hoping to improve the armamentarium for male patients with breast cancer through the issuance of industry guidelines aimed at encouraging the inclusion of male patients in breast cancer clinical trials. The industry guidelines, which are still in ...
Leggi tutto

Clinical outcomes in ovarian cancer patients receiving three versus more cycles of chemotherapy after neoadjuvant treatment and interval cytoreductive surgery

To compare clinical outcomes for stage IIIC and IV ovarian cancer patients receiving neoadjuvant chemotherapy and interval cytoreductive surgery followed by up to three versus more cycles of post-operative chemotherapy. We conducted a multi-institution retrospective cohort ...
Leggi tutto